Clinical trials: Neoplasms, Oral
Multiple Myeloma
An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics
- Trial name
- NCT02182141
- Testing
- BIBF 1120 ES
- Volunteers
- 17 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumours
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
This is a Phase 1, open-label, non-randomised, 3-arm (A, B, and C), drug-drug interaction study in patients with advanced solid tumours.
- Trial name
- NCT04959266
- Testing
- Adavosertib, Itraconazole, Rifampicin
- Where
- 5 sites in United States, Spain
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
This is a 2-part study in patients with epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung cancer (NSCLC) whose disease has progressed on treatment with an epidermal growth factor receptor…
- Trial name
- NCT02163733
- Testing
- AZD9291 tablets, Pharmacokinetic sampling - AZD9291, Dietary Fasted
- Where
- 13 sites in France, South Korea and 2 more
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Solid Tumor, Stage IV Gastric Cancer
A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer
A study of DHP107, a novel oral paclitaxel formulation, to determine maximum tolerated dose and recommended dose for phase II trial in patients with advanced solid cancer and explore efficacy of DHP107 in patients with gastric…
- Trial name
- NCT02890511
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
Chronic Myeloid Leukemia
TGRX-678 Phase I Oral Pharmacokinetic Study
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-678
- Trial name
- NCT06697899
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Solid Tumor, Solid Tumor, Adult
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of…
- Conditions
- Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor
- Trial name
- NCT06264921
- Testing
- NKT3447
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- NiKang Therapeutics, Inc.
Prostatic Neoplasms
Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
The primary objective of this study was to determine the safety and Maximum tolerated dose (MTD) of BIBF 1120 combination therapy with docetaxel and prednisone in patients with hormone refractory prostate cancer.
- Trial name
- NCT02182219
- Testing
- BIBF 1120
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Advanced Non-small Cell Lung Cancer
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
This is a Phase I/II, multi-center, open-label study, composed with a Phase I part (dose-escalation phase) followed by a Phase II part (expansion phase).
- Trial name
- NCT02108964
- Testing
- EGF816
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Advanced Solid Tumours
Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
To investigate the safety and tolerability of AZD8055 intermittent dosing schedules when given orally to patients with advanced solid malignancies and lymphomas.
- Conditions
- Cancer, Advanced Solid Tumours, Lymphomas
- Trial name
- NCT01194193
- Testing
- AZD8055
- Volunteers
- 63 people
- Sponsor
- AstraZeneca
Breast Cancer
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
The aim of this international open-label randomized phase II trial is to evaluate the efficacy and safety of an all-oral combination and two all-intravenous combinations as first-line therapy for HER2-negative mBC patients.
- Trial name
- NCT03887130
- Testing
- oral vinorelbine, Capecitabine, Gemcitabine 1250 mg/m²
- Volunteers
- 152 people
- Sponsor
- Pierre Fabre Medicament
Colorectal Cancer
A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution
A first study at one centre, with a new oral gut cleansing solution, NRL994, in patients who were going to have a colonoscopy. The study was to find out how well the new "Low Dose Bowel Prep" (LDBP) worked, and whether it was…
- Trial name
- NCT06597903
- Testing
- NRL994
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Norgine
Carcinoma, Non-Small-Cell Lung
BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)
The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.
- Trial name
- NCT00979576
- Testing
- BIBF 1120 M + Pemetrexed, BIBF 1120 H + Pemetrexed, BIBF 1120 RD + Pemetrexed
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated…
- Conditions
- Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant
- Trial name
- NCT06655246
- Testing
- ziftomenib, imatinib mesylate
- Where
- 32 sites in United States
- Volunteers
- 135 people
- Sponsor
- Kura Oncology, Inc.
Oral Mucositis
A Mouthwash Medicine for the Reduction or Prevention of Mouth Ulceration Caused by Radiotherapy for Head and Neck Cancer
This study is looking at a new medication called NG11-2 to see if it can reduce a side effect called severe Radiation-induced Oral Mucositis (RIOM) that can happen to people getting radiation treatment for head and neck cancer.
- Trial name
- NCT06669390
- Testing
- NG11-2
- Where
- 4 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- VasoDynamics Ltd
Advanced Metastatic Breast Cancer
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
- Trial name
- NCT01597388
- Testing
- AZD2014, Fulvestrant
- Where
- 5 sites in United States
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Oral Squamous Cell Carcinoma
Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer
The purpose of this study is to verify the discriminatory value of previously identified salivary transcriptome and proteome markers for oral squamous cell cancer in an intended use population of patients with oral lesions…
- Trial name
- NCT01587573
- Testing
- saliva collection prior to clinically driven oral biopsy
- Where
- 5 sites in United States
- Volunteers
- 370 people
- Sponsor
- PeriRx
Prostate Cancer
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
Assess whether the combination of ABT-888 with temozolomide (TMZ) has activity in subjects with metastatic castration resistant prostate cancer (CRPC) as reflected by the prostate-specific antigen (PSA) response.
- Trial name
- NCT01085422
- Testing
- ABT-888, temozolomide
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Neoplasms
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
The primary objective of the trial is to determine the maximum tolerated doses (MTD) of BI 860585 alone and in combination with exemestane or paclitaxel.
- Trial name
- NCT01938846
- Testing
- BI 860585, exemestane, paclitaxel
- Where
- 4 sites in Belgium, Italy
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Refractory Solid Tumor
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
This phase I study will be conducted in an open-label, conventional 3+3 dose escalation design manner (for the first 28 days of dosing) followed by an extension period for subjects responsive to the study drug to continue dosing…
- Trial name
- NCT03443622
- Testing
- SC-43 Oral Solution
- Sponsor
- SupremeCure Pharma Inc.
Breast Cancer
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
This 3 arm study will compare the prophylactic effect of topical corticosteroids, Bepantol or placebo on hand-foot syndrome in patients receiving Xeloda for treatment of metastatic breast cancer, metastatic colorectal cancer or…
- Trial name
- NCT00661102
- Testing
- Corticosteroids, capecitabine [Xeloda], dexpantenol [Bepantol]
- Where
- 35 sites in Brazil
- Volunteers
- 598 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.